Competing endogenous RNAs regulatory crosstalk networks: The messages from the RNA world to signaling pathways directing cancer stem cell development.

Cancer stem cells Competing endogenous RNAs Micro-RNA ceRNA lncRNA

Journal

Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560

Informations de publication

Date de publication:
15 Aug 2024
Historique:
received: 10 02 2024
revised: 08 07 2024
accepted: 24 07 2024
medline: 22 8 2024
pubmed: 22 8 2024
entrez: 22 8 2024
Statut: epublish

Résumé

Cancer stem cells (CSCs) are one of the cell types that account for cancer heterogeneity. The cancer cells arrest in G0 and generate non-CSC progeny through self-renewal and pluripotency, resulting in tumor recurrence, metastasis, and resistance to chemotherapy. They can stimulate tumor relapse and re-grow a metastatic tumor. So, CSCs is a promising target for eradicating tumors, and developing an anti-CSCs therapy has been considered. In recent years competing endogenous RNA (ceRNA) has emerged as a significant class of post-transcriptional regulators that affect gene expression via competition for microRNA (miRNA) binding. Furthermore, aberrant ceRNA expression is associated with tumor progression. Recent findings show that ceRNA network can cause tumor progression through the effect on CSCs. To overcome therapeutic resistance due to CSCs, we need to improve our current understanding of the mechanisms by which ceRNAs are implicated in CSC-related relapse. Thus, this review was designed to discuss the role of ceRNAs in CSCs' function. Targeting ceRNAs may open the path for new cancer therapeutic targets and can be used in clinical research.

Identifiants

pubmed: 39170516
doi: 10.1016/j.heliyon.2024.e35208
pii: S2405-8440(24)11239-X
pmc: PMC11337742
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

e35208

Informations de copyright

© 2024 The Authors.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Hamid Aria (H)

Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.
Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

Mahdieh Azizi (M)

Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

Shima Nazem (S)

Department of Clinical Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Behnam Mansoori (B)

Pediatrics Department, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran.

Farzaneh Darbeheshti (F)

Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Anoosha Niazmand (A)

Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

Abdolreza Daraei (A)

Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
Department of Medical Genetics, School of Medicine, Babol University of Medical Sciences, Babol, Iran.

Yaser Mansoori (Y)

Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.
Department of Medical Genetics, Fasa University of Medical Sciences, Fasa, Iran.

Classifications MeSH